In contrast with other cancers, the majority of melanomas express wild-type (WT) TP53. [14] Given that both MDM2 and TP53 genes are infrequently mutated in melanoma and that inhibition of MDM2 may activate p53’s tumor suppressor program, blocking the p53/MDM2 interaction may be an effective anticancer strategy for TP53-WT melanomas. This evidence concerns the gene MDM2 and neoplasm.